Navidea Biopharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0896
- Today's High:
- $0.0973
- Open Price:
- $0.0973
- 52W Low:
- $0.06
- 52W High:
- $0.35
- Prev. Close:
- $0.09
- Volume:
- 855907
Company Statistics
- Market Cap.:
- $9.27 million
- Book Value:
- -0.011
- Revenue TTM:
- $8126
- Operating Margin TTM:
- -128723.7%
- Gross Profit TTM:
- $-119295
- Profit Margin:
- 0%
- Return on Assets TTM:
- -121.93%
- Return on Equity TTM:
- -1100.12%
Company Profile
Navidea Biopharmaceuticals Inc had its IPO on 1992-11-10 under the ticker symbol NAVB.
The company operates in the Healthcare sector and Biotechnology industry. Navidea Biopharmaceuticals Inc has a staff strength of 11 employees.
Stock update
Shares of Navidea Biopharmaceuticals Inc opened at $0.1 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.09 - $0.1, and closed at $0.09.
This is a +3% increase from the previous day's closing price.
A total volume of 855,907 shares were traded at the close of the day’s session.
In the last one week, shares of Navidea Biopharmaceuticals Inc have increased by +15.88%.
Navidea Biopharmaceuticals Inc's Key Ratios
Navidea Biopharmaceuticals Inc has a market cap of $9.27 million, indicating a price to book ratio of 8.1624 and a price to sales ratio of 84.1435.
In the last 12-months Navidea Biopharmaceuticals Inc’s revenue was $8126 with a gross profit of $-119295 and an EBITDA of $-10354230. The EBITDA ratio measures Navidea Biopharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Navidea Biopharmaceuticals Inc’s operating margin was -128723.7% while its return on assets stood at -121.93% with a return of equity of -1100.12%.
In Q2, Navidea Biopharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.8%.
Navidea Biopharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.44 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Navidea Biopharmaceuticals Inc’s profitability.
Navidea Biopharmaceuticals Inc stock is trading at a EV to sales ratio of 437.3134 and a EV to EBITDA ratio of -0.4664. Its price to sales ratio in the trailing 12-months stood at 84.1435.
Navidea Biopharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $8.22 million
- Total Liabilities
- $8.31 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $65337
- Dividend Payout Ratio
- 0%
Navidea Biopharmaceuticals Inc ended 2024 with $8.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $8.22 million while shareholder equity stood at $-1079101.00.
Navidea Biopharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $8.31 million in other current liabilities, 287146.00 in common stock, $-383654144.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.14 million and cash and short-term investments were $6.14 million. The company’s total short-term debt was $1,338,135 while long-term debt stood at $0.
Navidea Biopharmaceuticals Inc’s total current assets stands at $7.00 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $44712.00 compared to accounts payable of $2.01 million and inventory worth $460746.00.
In 2024, Navidea Biopharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $65337.
Comparatively, Navidea Biopharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.09
- 52-Week High
- $0.35
- 52-Week Low
- $0.06
- Analyst Target Price
- $6.5
Navidea Biopharmaceuticals Inc stock is currently trading at $0.09 per share. It touched a 52-week high of $0.35 and a 52-week low of $0.35. Analysts tracking the stock have a 12-month average target price of $6.5.
Its 50-day moving average was $0.09 and 200-day moving average was $0.2 The short ratio stood at 0.17 indicating a short percent outstanding of 0%.
Around 3543.3% of the company’s stock are held by insiders while 159% are held by institutions.
Frequently Asked Questions About Navidea Biopharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi’s sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.